Claims for Patent: 6,258,791

Summary for Patent: 6,258,791

Title:	Combination product for enhanced gene delivery comprising a hyaluronidase
Abstract:	The invention relates to a composition, kit and methods of using the compositions and kits. The composition comprises a compound which disorganizes or degrades the extracellular matrix of a cell and a nucleic acid of interest. The composition or kit is contemplated for use in gene transfer and gene therapy.
Inventor(s):	Braun; Serge (Dorlisheim, FR)
Assignee:	Transgene S.A. (Strasbourg, FR)
Application Number:	09/424,741
Patent Claims:	1. A composition comprising at least a nucleic acid and at least one substance which disorganizes the extracellular matrix of a cell, said substance being a hyaluronidase, wherein said nucleic acid is contained in an infectious viral particle, a cationic lipid, a liposome or a cationic polymer. 2. The composition according to claim 1, wherein said hyaluronidase is a mammalian, reptilian or hymenopteran hyaluronate glycanohydrolase, a hyaluronate glycanohydrolase from the salivary gland of a leech, or a bacterial hyaluronate lyase. 3. The composition according to claim 1, wherein the nucleic acid is in the form of a recombinant adenoviral vector which is defective for replication. 4. The composition according to claim 3, wherein the adenoviral vector comprises at least ITRs and an encapsidation sequence and lacks all or part of adenoviral E1 region. 5. The composition according to claim 4, wherein the adenoviral vector additionally lacks all or part of the adenoviral E3 region. 6. The composition according to claim 4, wherein the adenoviral vector additionally lacks all or part of one or more regions selected from the adervirol E2, E4, L1, L2, L3, L4 and L5 regions. 7. The composition according to claim 1, which further comprises a pharmaceutically acceptable excipient. 8. A method for enhancing delivery of a nucleic acid into a human or an animal, said method comprising the step of administering hyaluronidase to the human or the animal prior to or in conjunction with an infectious viral particle or a complex comprising a nucleic acid and a cationic lipid, a liposome or a cationic polymer. 9. The method of claim 8, wherein said infectious viral particle or said complex comprising a nucleic acid and a cationic lipid, a liposome or a cationic polymer is administered simultaneously with said hyaluronidase. 10. The method of claim 8, wherein said infectious viral particle or said complex comprising a nucleic acid and a cationic lipid, a liposome or a cationic polymer is administered following the administration of hyaluronidase. 11. The method of claim 9, wherein said infectious particle is an adenoviral particle. 12. The method of claim 10, wherein said infectious viral particle is an adenoviral particle. 13. A kit for enhancing introduction of a nucleic acid into a cell comprising (i) at least a hyaluronidase and (ii) at least one nucleic acid wherein said nucleic acid is contained in an infectious viral particle, a cationic lipid, a liposome or a cationic polymer.

Details for Patent 6,258,791

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	May 05, 2004	6,258,791	2017-05-29
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	December 02, 2004	6,258,791	2017-05-29
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	October 26, 2004	6,258,791	2017-05-29
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	October 25, 2005	6,258,791	2017-05-29
Halozyme Therapeutics, Inc.	HYLENEX RECOMBINANT	hyaluronidase human	Injection	021859	December 02, 2005	6,258,791	2017-05-29